Oral bambuterol versus terbutaline in patients with asthma

https://doi.org/10.1016/0011-393X(95)85078-3Get rights and content

Abstract

This double-blind, crossover study compared the bronchodilating effects and side-effect profiles, including arrhythmogenic effects, of bambuterol tables 20 mg once every evening with terbutaline tablets 5 mg three times daily in 22 patients with asthma without concomitant heart disease. Peak expiratory flow, use of inhaled beta2-agonists, asthma symptoms, and adverse events were recorded daily during each 7-day treatment period. At the end of each period, forced expiratory volume in 1 second and 48-hour ambulatory electrocardiograms were monitored. There was no difference in lung function between treatments; however, the mean score for dyspnea during the night was significantly lower (P < 0.05) for bambuterol than for terbutaline (0.20 ± 0.09 vs 0.036 ± 0.10, respectively) as was the nighttime use of inhaled beta2-agonists (1.7 ± 0.5 vs 2.3 ± 0.5, respectively). No significant differences between treatments in arrhythmogenic effects were found. Few patients reported adverse events. However, the mean score for daytime uneasiness was significantly lower (P < 0.05) during treatment with bambuterol (0.05 ± 0.05) than with terbutaline (0.20 ± 0.09). Compared with terbutaline 5 mg three times daily, bambuterol 20 mg once every evening provides greater symptomatic relief of nocturnal asthma with a lower side-effect profile.

References (17)

There are more references available in the full text version of this article.

Cited by (18)

  • Prodrugs of triterpenoids and their derivatives

    2017, European Journal of Medicinal Chemistry
    Citation Excerpt :

    Prodrugs provide the possibilities to improve solubility, chemical stability, organoleptic property, and organ/tissue-selective delivery of the active agent, and to decrease presystemic metabolism and toxicity, which finally improves therapeutic index of the parent drugs [22,23]. Specifically, conjugation of parent drugs with phosphoric acids, sulfuric acids, amino acids, polymers, or sugars has been used to improve aqueous solubility and oral bioavailability [24–26]; masking of polar ionized groups or attachment of non-ionized functional groups (e.g. alkyl or aryl esters) has been applied to enhance lipophilicity and oral or topical absorption [20]; coupling of parent drugs with site-selective molecules has seen increased efficacy and safety [19]; protection of the metabolically labile but pharmacologically essential functional groups has shown decreased presystemic metabolism and prolonged time of drug release [27,28]. Since the late 19th century the prodrug strategy has been used to improve undesirable properties of potent drugs [29], and currently, about 10% of all globally marketed medicines can be classified as prodrugs.

  • Chronotherapeutics - A chronopharmaceutical approach to drug delivery in the treatment of asthma

    2012, Journal of Controlled Release
    Citation Excerpt :

    Bambuterol can therefore act as an inner depot from which terbutaline is slowly released. This slow-release mechanism results in a smooth and sustained plasma concentration of generated terbutaline [77–79]. Formoterol (Ciba Geigy, Europe) and salmeterol (Glaxo, UK and USA) are long-acting β2 agonist (LABA) aerosol medications, having prolonged bronchodilator activity (12 h) with substantial anti-inflammatory effect on airways, and little adverse effect [80,81].

  • Prodrug research: Futile or fertile?

    2004, Biochemical Pharmacology
    Citation Excerpt :

    A conceptually different and particularly elegant approach to slow metabolic release has been achieved with bambuterol, a prodrug of the β2-adrenoreceptor agonist terbutaline [31,32] (Fig. 4). Compared to terbutaline 5 mg taken three times daily, bambuterol 20 mg taken once daily provides smooth and sustained plasma levels of terbutaline, and a greater symptomatic relief of asthma with a lower incidence of side-effects [33]. Similar results were obtained when comparing a slow-release formulation of terbutaline 10 mg with bambuterol 0.085 mg kg−1[34].

View all citing articles on Scopus
View full text